Repositioning Candidate Details
Candidate ID: | R0749 |
Source ID: | DB05235 |
Source Type: | investigational |
Compound Type: | small molecule |
Compound Name: | NRP409 |
Synonyms: | -- |
Molecular Formula: | -- |
SMILES: | -- |
DrugBank Description: | NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism. |
CAS Number: | -- |
Molecular Weight: | |
DrugBank Indication: | For use in treatment of hypothyroidism. |
DrugBank Pharmacology: | The company is hoping that NRP409 will mark a significant improvement in thyroid HRT by reducing the variability of the more active hormone's availability, while reducing the safety risk associated with other T3 based therapies. |
DrugBank MoA: | NRP409 is presumed to work like the endogenous thyroid hormone thyroxine (T<sub>4</sub>, a tetra-iodinated tyrosine derivative). In the liver and kidney, T<sub>4</sub> is converted to T<sub>3</sub>, the active metabolite. In order to increase solubility, the thyroid hormones attach to thyroid hormone binding proteins, thyroxin-binding globulin, and thyroxin-binding prealbumin (transthyretin). Transport and binding to thyroid hormone receptors in the cytoplasm and nucleus then takes place. Thus by acting as a replacement for natural thyroxine, symptoms of thyroxine deficiency are relieved. |
Targets: | Ketimine reductase mu-crystallin; Thyroid hormone receptor alpha |
Inclusion Criteria: | Indication associated |

Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
---|
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|